Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Molecules ; 27(9):2754, 2022.
Article in English | ProQuest Central | ID: covidwho-1842799

ABSTRACT

Commonly used clinical chemotherapy drugs, such as cyclophosphamide (CTX), may cause injury to the ovaries. Hormone therapies can reduce the ovarian injury risk;however, they do not achieve the desired effect and have obvious side effects. Therefore, it is necessary to find a potential therapeutic candidate for ovarian injury after chemotherapy. N-Benzyl docosahexaenamide (NB-DHA) is a docosahexaenoic acid derivative. It was recently identified as the specific macamide with a high degree of unsaturation in maca (Lepidium meyenii). In this study, the purified NB-DHA was administered intragastrically to the mice with CTX-induced ovarian injury at three dose levels. Blood and tissue samples were collected to assess the regulation of NB-DHA on ovarian function. The results indicated that NB-DHA was effective in improving the disorder of estrous cycle, and the CTX+NB-H group can be recovered to normal levels. NB-DHA also significantly increased the number of primordial follicles, especially in the CTX+NB-M and CTX+NB-H groups. Follicle-stimulating hormone and luteinizing hormone levels in all treatment groups and estradiol levels in the CTX+NB-H group returned to normal. mRNA expression of ovarian development-related genes was positive regulated. The proportion of granulosa cell apoptosis decreased significantly, especially in the CTX+NB-H group. The expression of anti-Müllerian hormone and follicle-stimulating hormone receptor significantly increased in ovarian tissues after NB-DHA treatment. NB-DHA may be a promising agent for treating ovarian injury.

2.
Drug Discov Today ; 26(10): 2358-2366, 2021 10.
Article in English | MEDLINE | ID: covidwho-1193286

ABSTRACT

The infectious disease Coronavirus 2019 (COVID-19) continues to cause a global pandemic and, thus, the need for effective therapeutics remains urgent. Global research targeting COVID-19 treatments has produced numerous therapy-related data and established data repositories. However, these data are disseminated throughout the literature and web resources, which could lead to a reduction in the levels of their use. In this review, we introduce resource repositories for the development of COVID-19 therapeutics, from the genome and proteome to antiviral drugs, vaccines, and monoclonal antibodies. We briefly describe the data and usage, and how they advance research for therapies. Finally, we discuss the opportunities and challenges to preventing the pandemic from developing further.


Subject(s)
COVID-19 Drug Treatment , Drug Discovery/trends , Internet/trends , Animals , Antibodies, Monoclonal/therapeutic use , Antiviral Agents/therapeutic use , Big Data , COVID-19 Vaccines/therapeutic use , Computational Biology , Humans
3.
Virtual Reality & Intelligent Hardware ; 2(4):368-380, 2020.
Article | WHO COVID | ID: covidwho-741536

ABSTRACT

Background Real-time 3D rendering and interaction is important for virtual reality (VR) experimental education. Unfortunately, standard end-computing methods prohibitively escalate computational costs. Thus, reducing or distributing these requirements needs urgent attention, especially in light of the COVID-19 pandemic Methods In this study, we design a cloud-to-end rendering and storage system for VR experimental education comprising two models: background and interactive. The cloud server renders items in the background and sends the results to an end terminal in a video stream. Interactive models are then lightweight-rendered and blended at the end terminal. An improved 3D warping and hole-filling algorithm is also proposed to improve image quality when the user’s viewpoint changes. Results We build three scenes to test image quality and network latency. The results show that our system can render 3D experimental education scenes with higher image quality and lower latency than any other cloud rendering systems. Conclusions Our study is the first to use cloud and lightweight rendering for VR experimental education. The results demonstrate that our system provides good rendering experience without exceeding computation costs.

4.
medrxiv; 2020.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2020.03.27.20043836

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) quickly became a major epidemic threat in the whole China. We analysed SARS-Cov-2 infected cases from Tibetan Autonomous Prefecture, and noted divergent characteristics of these Tibetans infected cases compared to Han Chinese, characterizing by a considerable proportion of asymptomatic carriers (21.7%), and few symptomatic patients with initial symptom of fever (7.7%). Here, we did a descriptive study on clinical characteristics of 18 asymptomatic individuals with SARS-CoV-2 infection. The median age of these asymptomatic carriers was 31 years and one third of them were students, aged under 20 years. Notably, some of asymptomatic carriers had recognizable changes in radiological and laboratory indexes. Our finding indicates a potentially big number of SARS-CoV-2 asymptomatic carriers in prevalent area, highlighting a necessity of screening individuals with close contact of infected patients, for a better control on the spread of SARS-CoV-2 infection.


Subject(s)
COVID-19 , Fever , Infections
5.
ChiCTR; 2020-02-24; TrialID: ChiCTR2000030164
Clinical Trial Register | ICTRP | ID: ictrp-ChiCTR2000030164

ABSTRACT

Condition:

Novel Coronavirus Pneumonia (COVID-19)

Intervention:

Case series:N/A;

Primary outcome:

the daily treatment intensity;

Criteria:

Inclusion criteria: All patients with SARS-CoV-2 pneumonia in the ICU

Exclusion criteria: none

SELECTION OF CITATIONS
SEARCH DETAIL